Cargando…
Clinical significance of TP53 variants as possible secondary findings in tumor-only next-generation sequencing
In tumor-only next-generation sequencing (NGS), identified variants have the potential to be secondary findings (SFs), but they require verification through additional germline testing. In the present study, 194 patients with advanced cancer who underwent tumor-only NGS between April 2015 and March...
Autores principales: | Yamamoto, Yoshihiro, Kanai, Masashi, Kou, Tadayuki, Sugiyama, Aiko, Nakamura, Eijiro, Miyake, Hidehiko, Yamada, Takahiro, Nishigaki, Masakazu, Kondo, Tomohiro, Murakami, Hiromi, Torishima, Masako, Matsumoto, Shigemi, Kosugi, Shinji, Muto, Manabu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917569/ https://www.ncbi.nlm.nih.gov/pubmed/31628423 http://dx.doi.org/10.1038/s10038-019-0681-6 |
Ejemplares similares
-
Clinical sequencing using a next‐generation sequencing‐based multiplex gene assay in patients with advanced solid tumors
por: Kou, Tadayuki, et al.
Publicado: (2017) -
Prevalence of pathogenic germline variants in the circulating tumor DNA testing
por: Yamamoto, Yoshihiro, et al.
Publicado: (2022) -
Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer
por: Kondo, Tomohiro, et al.
Publicado: (2018) -
Inter-assay variability of next-generation sequencing-based gene panels
por: Quy, Pham Nguyen, et al.
Publicado: (2022) -
Negative recollections regarding doctor–patient interactions among men receiving a prostate cancer diagnosis: a qualitative study of patient experiences in Japan
por: Torishima, Masako, et al.
Publicado: (2020)